RE:Green Profit...(Net Profit).The 4001+ tests volume mentioned in my post (below) is based on a presentation made in Q1 2018, before ''AIM Laboratories'' and ''LifeX'' came on board.
AIM Laboratories came on board in May 2018 with a big distribution network that cover 20+ states...before long to be able to accomodate the increase in tests volume created by this new alliance Genenews will have to increase its laboratories staff.
My guess (only a guess) is that the new number should be between 5000 & 6000 tests volume a month to cover the rise in day to day expense.
This increase would be good news, as it would indicate that total tests volume and future positive profit margins will increase accordingly.
Some posters on this board live in the past.
The Genenews we see today is a completely new and revamped company. Genenews is at a point of inflection, in the last few months Genenews made a sequence of actions that clearly indicate that they are heading toward positive profit margins.
Note: Last week a puny little amount of shares were exchanged at a price of .045$, the majorities of Genenews shareholders are not impress by these futile tactics to grab shares at a lower price and are holding on to their shares in view of expected good news in the coming weeks.
wildbird1 wrote: In my last post I made allusion to the fact that once Genenews achieve ''Green Profit''
it will wake-up the market to the huge potential of genenews cancer tests.
For investors that are not very familiar with ''Green Profit'' (Net profit), let's shed some light on it.
Let's assume that Genenews need a test volume of approximately 4000 tests a month to cover day to day expense (equipment, research, salary ect...) if genenews test volume is 4001 (4000+1) the +1 is '' Green profit.
In the last few months we have had new development that clearly indicate that Genenews is closer than ever to that 4001+ goal (we all hope it is already over that number).
- New billing process, that is finally working to the advantage of Genenews.
- New partners to distribute Genenews tests(AIM).
-New and powerfull partner '' LifeX '' (with big contacts, like the University of Pittsburg Huge Medical center, Pfizer...ect).
-New Chief Commercial Officer whose job is to insuflate a new life in the sale and marketing team.
- And to top it off, possibly a very big increase in tests volume in the month of July, Aug & Sept 2018(40%+).
Will it be enough to break that 4001 target, my guess is that if we don't break it will be very very close.
After that first 4001+ tests volume target, the next step will be to sustain positive grow in tests volume Quarter after Quarter.
Sustaining steady grow should be easy since Genenews has innovative technologies in a poorly served 70 Billion dollard market.
Hold on to your Genenews shares, relax and enjoy the ride.